Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Nicolaas Schaap"'
Autor:
Sonja Zweegman, Nicolaas Schaap, Peter A. W. te Boekhorst, Sabina Kersting, Harry R. Koene, Stefanie Slot, Matthijs Westerman, Reinier Raymakers, Harry C. Schouten, Lambert F.R. Span
Publikováno v:
Clinical Lymphoma, Myeloma and Leukemia, 19(10), 624. Cancer Media Group
Clinical Lymphoma Myeloma & Leukemia, 19, 10, pp. 624-634
Clinical Lymphoma Myeloma & Leukemia, 19(10), 624-634. Cancer Media Group
Slot, S, Raymakers, R A P, Schaap, N, Span, L F R, Koene, H R, Kersting, S, te Boekhorst, P A W, Westerman, M, Schouten, H C & Zweegman, S 2019, ' Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature ', Clinical Lymphoma, Myeloma and Leukemia, vol. 19, no. 10, pp. 624-634 . https://doi.org/10.1016/j.clml.2019.07.005
Clinical Lymphoma, Myeloma and Leukemia, 19(10), 624-634. Cancer Media Group
Clinical Lymphoma Myeloma & Leukemia, 19, 624-634
Clinical Lymphoma Myeloma & Leukemia, 19, 10, pp. 624-634
Clinical Lymphoma Myeloma & Leukemia, 19(10), 624-634. Cancer Media Group
Slot, S, Raymakers, R A P, Schaap, N, Span, L F R, Koene, H R, Kersting, S, te Boekhorst, P A W, Westerman, M, Schouten, H C & Zweegman, S 2019, ' Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature ', Clinical Lymphoma, Myeloma and Leukemia, vol. 19, no. 10, pp. 624-634 . https://doi.org/10.1016/j.clml.2019.07.005
Clinical Lymphoma, Myeloma and Leukemia, 19(10), 624-634. Cancer Media Group
Clinical Lymphoma Myeloma & Leukemia, 19, 624-634
Real-life data on the treatment of myelofibrosis patients with baseline thrombocytopenia with ruxolitinib are limited. We present the outcomes of thrombocytopenic Dutch patients treated within a compassionate-use program. Additionally, we performed a
Autor:
Grzegorz W. Basak, Jiri Mayer, Soledad González Muñiz, Paul Bosman, Giulia Sbianchi, Johan Lund, Jane F. Apperley, Guido Kobbe, Stig Lenhoff, Sarah Lawless, Curly Morris, Cecilia Isaksson, Esa Jantunen, Achilles Anagnostopoulos, Paul Browne, Jennifer Byrne, Didier Blaise, Simona Iacobelli, Alessandro Rambaldi, Ibrahim Yakoub-Agha, Péter Reményi, Nicolaas Schaap, Keith M.O. Wilson, Stefan Schönland, Nicolaus Kröger, Christof Scheid, Cyrille Touzeau, Laurent Garderet
Publikováno v:
Clinical Lymphoma Myeloma & Leukemia, 21, 686-693
Clinical Lymphoma, Myeloma and Leukemia, 21(10), 686-693. CIG MEDIA GROUP, LP
Clinical Lymphoma Myeloma & Leukemia, 21, 10, pp. 686-693
Clinical Lymphoma, Myeloma and Leukemia, 21(10), 686-693. CIG MEDIA GROUP, LP
Clinical Lymphoma Myeloma & Leukemia, 21, 10, pp. 686-693
The rare myelomas, immunoglobulin (Ig)D, IgM, and non-secretory, have been associated with poorer outcomes following treatment than the common myelomas (IgG, IgA, and light-chain only). We show that even with "novel" therapies, augmented with autolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c144cc4a414ce17f2a367c91656e25de
https://hdl.handle.net/1887/3281911
https://hdl.handle.net/1887/3281911
Autor:
Mutlu Arat, Jenny Byrne, Ibrahim Yakoub-Agha, Sascha Dietrich, Johanna Tischer, Federica Sorà, Nicolaas Schaap, Eleni Tholouli, Francis Ayuk, Joan Hendrik Veelken, Yves Chalandon, Yener Koc, Henric Jan Blok, Johan Maertens, Per Ljungman, Maija Itälä-Remes, Jürgen Finke, Pavel Jindra, Jiri Mayer, Michael Stadler, Gérard Socié, Vanderson Rocha, Jakob Passweg, Arnon Nagler, Nicolaus Kröger, Aleksandar Radujkovic
Publikováno v:
Biology of Blood and Marrow Transplantation, 25, 10, pp. 2008-2016
Biology of Blood and Marrow Transplantation, Vol. 25, No 10 (2019) pp. 2008-2016
Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, 25, 2008-2016
Biology of Blood and Marrow Transplantation, 25(10), 2008-2016. ELSEVIER SCIENCE INC
Biology of Blood and Marrow Transplantation, Vol. 25, No 10 (2019) pp. 2008-2016
Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, 25, 2008-2016
Biology of Blood and Marrow Transplantation, 25(10), 2008-2016. ELSEVIER SCIENCE INC
The prognosis of patients with blast crisis (BC) chronic myeloid leukemia (CML) is still dismal. Allogeneic stem cell transplantation represents the only curative treatment option, but data on transplant outcomes are scarce. We therefore conducted a
Autor:
Gloria Tridello, Didier Blaise, Patrice Chevallier, Grzegorz W. Basak, Eric Deconinck, Jan Styczyński, Nicolaus Kröger, Diana Averbuch, Ibrahim Yakoub-Agha, Silvia Montoto, Nicolaas Schaap, Edouard Forcade, Rafael de la Cámara, Nina Knelange, Stephanie Nguyen-Quoc, Jakob Passweg, Catherine Cordonnier, Lidia Gil, Jan J. Cornelissen, Mauricette Michallet, Simone Cesaro, Katherine N. Ward, Nigel H. Russell, Gérard Socié, Eefke Petersen, Per Ljungman, Hendrik Veelken, Nathalie Fegueux, Peter Bader, Malgorzata Mikulska, Johan Maertens
Publikováno v:
Bone Marrow Transplantation, 54(12), 2060-2071. Nature Publishing Group
Bone Marrow Transplantation, 54(12), 2060-2071. NATURE PUBLISHING GROUP
Bone Marrow Transplantation, 54, 12, pp. 2060-2071
Bone Marrow Transplantation, 54, 2060-2071
Bone Marrow Transplantation, 54(12), 2060-2071. NATURE PUBLISHING GROUP
Bone Marrow Transplantation, 54, 12, pp. 2060-2071
Bone Marrow Transplantation, 54, 2060-2071
The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients
Autor:
Johannes Schetelig, Henning Baldauf, Linda Koster, Michelle Kuxhausen, Falk Heidenreich, Liesbeth C. de Wreede, Stephen Spellman, Michel van Gelder, Benedetto Bruno, Francesco Onida, Vinzenz Lange, Carolin Massalski, Victoria Potter, Per Ljungman, Nicolaas Schaap, Patrick Hayden, Stephanie J. Lee, Nicolaus Kröger, Kathy Hsu, Alexander H. Schmidt, Ibrahim Yakoub-Agha, Marie Robin
Publikováno v:
Frontiers in Immunology, 11. FRONTIERS MEDIA SA
Frontiers in Immunology, 11:584520. Frontiers Media S.A.
Frontiers in Immunology, 11
Frontiers in Immunology
Frontiers in Immunology, Vol 11 (2021)
Frontiers in Immunology, 11:584520. Frontiers Media S.A.
Frontiers in Immunology, 11
Frontiers in Immunology
Frontiers in Immunology, Vol 11 (2021)
Results from registry studies suggest that harnessing Natural Killer (NK) cell reactivity mediated through Killer cell Immunoglobulin-like Receptors (KIR) could reduce the risk of relapse after allogeneic Hematopoietic Cell Transplantation (HCT). Sev
Autor:
Myriam Labopin, Eefke Petersen, Jürgen Finke, Mohamad Mohty, Christoph Schmid, Donald Bunjes, Jan J. Cornelissen, Dietrich W. Beelen, Tobias Gedde-Dahl, Bipin N. Savani, Arnon Nagler, Nicolaus Kröger, Nicolaas Schaap, Montserrat Rovira, Johanna Waidhauser, Gwendolyn Van Gorkom, Jordi Esteve
Publikováno v:
Bone Marrow Transplantation, 56, 2445-2453
Bone Marrow Transplantation, 56(10), 2445-2453. Nature Publishing Group
Bone Marrow Transplantation
Bone Marrow Transplantation, 2021, ⟨10.1038/s41409-021-01322-w⟩
Bone Marrow Transplantation, 56, 10, pp. 2445-2453
Bone Marrow Transplantation, Nature Publishing Group, 2021, ⟨10.1038/s41409-021-01322-w⟩
Bone Marrow Transplantation, 56(10), 2445-2453. Nature Publishing Group
Bone Marrow Transplantation
Bone Marrow Transplantation, 2021, ⟨10.1038/s41409-021-01322-w⟩
Bone Marrow Transplantation, 56, 10, pp. 2445-2453
Bone Marrow Transplantation, Nature Publishing Group, 2021, ⟨10.1038/s41409-021-01322-w⟩
Acute myeloid leukemia with runt-related transcription factor 1 gene mutation (RUNX1+ AML) is associated with inferior response rates and outcome after conventional chemotherapy. We performed a retrospective, registry-based analysis to elucidate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cb9bd24eca641c014554135ee74ff3b
http://hdl.handle.net/2066/243910
http://hdl.handle.net/2066/243910
Autor:
Dietrich W. Beelen, Nicola Di Renzo, Nicolaas Schaap, Katja Sockel, Peter A. von dem Borne, Patrick Hayden, Zeynep Arzu Yegin, Jakob Passweg, Giulia Sbianchi, Elena V. Morozova, Marie-Thérèse Rubio, Nicolaus Kröger, Francesca Patriarca, Christine Wolschke, Ibrahim Yakoub-Agha, Donal McLornan, Paolo Bernasconi, Johannes Clausen, Tiarlan Sirait, Marie Robin, Jürgen Finke, Radovan Vrhovac, Grzegorz Helbig, Eibhlin Conneally, Wilfried Schroyens, Yves Beguin
Publikováno v:
Leukemia
Leukemia, 35, 3551-3560. SPRINGERNATURE
Leukemia, 2021, 35 (12), pp.3551-3560. ⟨10.1038/s41375-021-01276-4⟩
Leukemia, 35, 12, pp. 3551-3560
Leukemia, 35, 3551-3560
Leukemia, 35, 3551-3560. SPRINGERNATURE
Leukemia, 2021, 35 (12), pp.3551-3560. ⟨10.1038/s41375-021-01276-4⟩
Leukemia, 35, 12, pp. 3551-3560
Leukemia, 35, 3551-3560
JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::212303e866b3dd2753322399dfbf4659
https://www.ncbi.nlm.nih.gov/pubmed/34023851
https://www.ncbi.nlm.nih.gov/pubmed/34023851
Autor:
Moshe Talpaz, Carrie Brownstein, Tymara Berry, Juan Shen, Eric Jourdan, Srdan Verstovsek, Nicolaas Schaap, Claire N. Harrison, Harry C. Schouten, Richard T. Silver, Shelonitda Rose, Ruben A. Mesa, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Sonja Zweegman, Francesco Passamonti
Publikováno v:
American Journal of Hematology, 95(6), 594-603. Wiley
American Journal of Hematology, 95, 594-603
American Journal of Hematology
Harrison, C N, Schaap, N, Vannucchi, A M, Kiladjian, J J, Jourdan, E, Silver, R T, Schouten, H C, Passamonti, F, Zweegman, S, Talpaz, M, Verstovsek, S, Rose, S, Shen, J, Berry, T, Brownstein, C & Mesa, R A 2020, ' Fedratinib in patients with myelofibrosis previously treated with ruxolitinib : An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure ', American Journal of Hematology, vol. 95, no. 6, pp. 594-603 . https://doi.org/10.1002/ajh.25777
American Journal of Hematology, 95, 6, pp. 594-603
American Journal of Hematology, 95(6), 594-603. Wiley-Liss Inc.
American Journal of Hematology, 95, 594-603
American Journal of Hematology
Harrison, C N, Schaap, N, Vannucchi, A M, Kiladjian, J J, Jourdan, E, Silver, R T, Schouten, H C, Passamonti, F, Zweegman, S, Talpaz, M, Verstovsek, S, Rose, S, Shen, J, Berry, T, Brownstein, C & Mesa, R A 2020, ' Fedratinib in patients with myelofibrosis previously treated with ruxolitinib : An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure ', American Journal of Hematology, vol. 95, no. 6, pp. 594-603 . https://doi.org/10.1002/ajh.25777
American Journal of Hematology, 95, 6, pp. 594-603
American Journal of Hematology, 95(6), 594-603. Wiley-Liss Inc.
Contains fulltext : 220650.pdf (Publisher’s version ) (Open Access) Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate- or high-risk myelofibrosis (MF) who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58c760202f3ed0846e8d53c2418d1bb1
https://cris.maastrichtuniversity.nl/en/publications/ab793601-9c16-42c0-9fb3-e453a23756e7
https://cris.maastrichtuniversity.nl/en/publications/ab793601-9c16-42c0-9fb3-e453a23756e7
Autor:
Ibrahim Yakoub-Agha, Xavier Poiré, Marek Trneny, Wilfried Schroyens, Linda Koster, Juan Bargay Lleonart, Denis Caillot, Péter Reményi, Nicolaas Schaap, Loic Fouillard, Anastasia Pouli, Maija Itälä-Remes, Dominique Bron, Nico Gagelmann, Vincenzo Pavone, Didier Blaise, Jean-Yves Cahn, Johan Maertens, Nicolaus Kröger, Rocio Parody Porras, Pietro Pioltelli, Roland Fenk, Jakob Passweg, Diderik Jan Eikema, Maurizio Musso, Stefan Schönland, Laurent Garderet
Publikováno v:
Biology of blood and marrow transplantation
Biology of Blood and Marrow Transplantation, 25, 11, pp. 2134-2142
Biology of Blood and Marrow Transplantation, 25, 2134-2142
Biology of blood and marrow transplantation, Vol. 25, no.11, p. 2134-2142 (2019)
Biology of Blood and Marrow Transplantation, 25, 11, pp. 2134-2142
Biology of Blood and Marrow Transplantation, 25, 2134-2142
Biology of blood and marrow transplantation, Vol. 25, no.11, p. 2134-2142 (2019)
Although high-dose therapy and autologous stem cell transplant combined with novel agents continues to be the hallmark of first-line treatment in newly diagnosed transplant-eligible multiple myeloma patients, the impact of tandem autologous or autolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c756da7aef0ec31fe79a73fa5e8e3b2c
https://lirias.kuleuven.be/handle/123456789/639716
https://lirias.kuleuven.be/handle/123456789/639716
Autor:
Didier Blaise, Soledad González Muñiz, Jane F. Apperley, Nicolaus Kröger, Péter Reményi, Nicolaas Schaap, Firoozeh Sahebi, Stig Lenhoff, Ibrahim Yakoub-Agha, Marta Krejčí, Nigel H. Russell, Giulia Sbianchi, Marek Trneny, Guido Kobbe, Wieslaw Wiktor-Jedrzejczak, Cecilia Isaksson, Christof Scheid, Stefan Schönland, Laurent Garderet, Curly Morris, Per Ljungman, Paul Browne, Linda Koster, Simona Iacobelli, James F. Sanchez, Keith Wilson
Publikováno v:
Biology of Blood and Marrow Transplantation, 24, 930-936
Biology of Blood and Marrow Transplantation, 24, 5, pp. 930-936
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (5), pp.930-936. ⟨10.1016/j.bbmt.2018.01.006⟩
Biology of Blood and Marrow Transplantation, 24, 5, pp. 930-936
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (5), pp.930-936. ⟨10.1016/j.bbmt.2018.01.006⟩
The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPM5). We examined the SPM rate in MM patients who were enrolled in the prospective observational CALM (Collaboration